Koers Mabvax Therapeutics Holdings Inc Nasdaq
Aandelen
US55414P5044
Biotechnologie & Medisch Onderzoek
Omzet 2016 | 148K 136K | Omzet 2017 | - | Marktkapitalisatie | 14,41 mln. 13,27 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -17 mln. -15,65 mln. | Nettowinst (verlies) 2017 | -19 mln. -17,49 mln. | EV/omzet 2016 | 147 x |
Nettoschuld 2016 | 470K 433K | Nettoschuld 2017 | 2,48 mln. 2,28 mln. | EV/omzet 2017 | - |
K/w-verhouding 2016 |
-0,93
x | K/w-verhouding 2017 |
-0,25
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 92,02% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08-07-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,29% | 113 mld. | |
+10,21% | 106 mld. | |
+0,41% | 22,27 mld. | |
-11,90% | 22,22 mld. | |
-5,99% | 19,43 mld. | |
-37,36% | 17,87 mld. | |
-5,17% | 17,24 mld. | |
+7,70% | 14,29 mld. | |
+37,65% | 12,52 mld. |